Search clinical trials for: Placebo matching BMS-929075

Total 1432 results

Bristol-Myers Squibb

Withdrawn

Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients

Chronic Hepatitis C

Australia
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

Ulcerative Colitis

United States
Bristol-Myers Squibb

Completed

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Alzheimer's Disease

France, Sweden, United States, Germany, Canada
Bristol-Myers Squibb

Completed

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

Depression

Japan
Bristol-Myers Squibb

Completed

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Mexico, Australia, Colombia, Chile, Peru
Bristol-Myers Squibb

Terminated

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Diabetic Kidney Disease

United States, Canada, Denmark, France
Bristol-Myers Squibb

Terminated

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Paroxysmal Atrial Fibrillation

United States, Canada
Hoffmann-La Roche

Completed

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

Healthy Adults

United States
Bristol-Myers Squibb

Terminated

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

Hypertension

Sweden, United States, Puerto Rico, Hungary, Colombia
Bristol-Myers Squibb

Terminated

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Depression

France, South Africa, Sweden, United States, Australia, Italy, Argentina, Austria, Spain, Finland, India, Puerto Rico
Bristol-Myers Squibb

Completed

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

Diabetes Mellitus Type 2

United States, Canada
Bristol-Myers Squibb

Completed

Japanese Phase 1 Multiple Ascending Dose Study

Type 2 Diabetes Mellitus

Japan
CSL Behring

Terminated

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

Germany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom
Bristol-Myers Squibb

Terminated

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease

United States
Bristol-Myers Squibb

Withdrawn

Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

Atherosclerotic Cardiovascular Disease
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
Bristol-Myers Squibb

Completed

Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins

Atherosclerosis

United States
Bristol-Myers Squibb

Completed

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

Alzheimer's Disease
Bristol-Myers Squibb

Completed

A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

Healthy | Hepatitis C

United States, Puerto Rico
Bristol-Myers Squibb

Completed

A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis

Healthy Subjects and Atopic Dermatitis Subjects

United Kingdom
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

Lupus

Taiwan, United States, Canada, Italy, Mexico, South Africa, Korea, Republic of, Japan, France, Spain, Argentina, Hungary, Colombia, Peru, Poland, Puerto Rico, Romania, Brazil, Chile, Germany, Lebanon, Netherlands, Russian Federation
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Melanoma | Skin Cancer

United States, Canada, Netherlands, Spain, Australia, Italy, Japan, Germany, Ireland, United Kingdom, Czechia, Switzerland, Poland, France, Greece, New Zealand
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)

Melanoma

Canada, Australia, Germany, Italy, Poland, France, Denmark, Argentina, Chile, Spain, Norway, Israel, Sweden, Mexico, Greece, Finland
Bristol-Myers Squibb

Completed

Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects

Healthy Adult Normals

United States
Bristol-Myers Squibb

Terminated

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Healthy Adult Volunteers

United States
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Bristol-Myers Squibb

Completed

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Hepatitis C

United States, Australia, Canada, France
Syneos Health
Shanghai Novamab Biopharmaceuticals Co. Ltd.

Terminated

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

Asthma

Australia
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
GlaxoSmithKline

Recruiting

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN)

Eosinophilic Granulomatosis With Polyangiitis

Canada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
Bristol-Myers Squibb

Terminated

Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

Healthy Volunteers | Ulcerative Colitis

Australia, Georgia, Moldova, Republic of
Janssen Research & Development, LLC

Completed

A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

Healthy

Netherlands
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

Asthma; Allergic Rhinitis

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis

China, United States, Japan, Korea, Republic of, Taiwan, Hungary, Canada, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Mexico, Netherlands, Peru, Polan... and more
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China, Taiwan, United States, Australia, Japan, Korea, Republic of, United Kingdom, Canada, Israel, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, ... and more
Bristol-Myers Squibb

Completed

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

Heart Decompensation, Acute

United States
CSL Behring

Completed

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Italy, United States, France, Argentina, Mexico, Japan, Canada, Hungary, South Africa
Anji Pharma
Covance

Completed

A Proof of Concept Study of Pradigastat in Patients With Functional Constipation

Functional Constipation

China, United States
YSOPIA Bioscience

Completed

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults (CAUSALITY)

Obesity | Metabolic Disease

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers

Venous Thrombosis
Bristol-Myers Squibb

Terminated

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Sjögren's Syndrome

Australia, United States, Italy, Mexico, Colombia, Peru, Puerto Rico, South Africa, Chile, Poland, Russian Federation
Bristol-Myers Squibb

Completed

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Pulmonary Fibrosis

Canada, France, United States, Argentina, Australia, Belgium, Brazil, Chile, China, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Lupus Erythematosus, Cutaneous

Germany
Immune Design

Terminated

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Sarcoma | Soft Tissue Sarcoma | Cancer | Synovial Sarcoma | Metastatic Sarcoma

United States, Canada

3

Subscribe